预约演示
更新于：2025-09-05
Dydrogesterone
地屈孕酮
更新于：2025-09-05
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H28O2 |
InChIKeyJGMOKGBVKVMRFX-HQZYFCCVSA-N |
CAS号152-62-5 |
关联
163
项与 地屈孕酮 相关的临床试验ChiCTR2500105270
Comparison of the effect of combination of alprosterone and dydrogesterone on luteal support after fresh cycle transplantation
CTR20251751
地屈孕酮片在中国健康受试者中单剂量、两制剂、四周期、两序列、随机、开放、完全重复交叉的空腹和餐后状态下生物等效性试验
CTR20251220
地屈孕酮片在中国健康人群中空腹和餐后状态下单次给药的人体生物等效性临床试验
100 项与 地屈孕酮 相关的临床结果
登录后查看更多信息
100 项与 地屈孕酮 相关的转化医学
登录后查看更多信息
100 项与 地屈孕酮 相关的专利（医药）
登录后查看更多信息
992
项与 地屈孕酮 相关的文献（医药）2025-09-01JOURNAL OF ETHNOPHARMACOLOGY
Exploring the inhibitory effects of Guben Antai Decoction on oxidative stress damage and ferroptosis via the Nrf2/HO-1 pathway: A mechanistic study on improving Recurrent Spontaneous Abortion
Article
作者: Li, Yongwei ; Wang, Chunxia ; Du, Xin ; Li, Xuebing ; Han, Mingyue ; Zhang, Xin ; Lu, Ruici ; Yang, Bingyao ; Su, Zhuoxuan
ETHNOPHARMACOLOGICAL RELEVANCE:
Guben Antai Decoction (GBAT) is a traditional Chinese medicine formula that significantly increases embryo implantation rates and reduces early pregnancy loss in patients with recurrent spontaneous abortion (RSA).
AIM OF THE STUDY:
This study aims to explore the influence and possible mechanism of GBAT in improving recurrent spontaneous abortion.
MATERIALS AND METHODS:
In vivo, normal pregnancy and RSA models were established using CBA/J female × BALB/c male and CBA/J female × DBA/2 male mouse pairings, respectively. GBAT (18.05 g/kg/d) or dydrogesterone (DYD; 3.03 mg/kg/d) was intragastrically administered to pregnant mice in the RSA model from gestational day 1. An oxidative stress model was established in vitro by treating human trophoblast HTR-8/SVneo cells with H2O2. Placental villi damage was assessed using hematoxylin and eosin staining, and mitochondrial morphology was examined using transmission electron microscopy. The expression of GPX4, ACSL4, SLC7A11, Nrf2, and HO-1 were measured using RT-qPCR, western blotting, and immunohistochemistry. Lipid peroxidation markers ROS, GSH, GPx, MDA, and Fe2+ were quantified using commercial kits.
RESULTS:
In mice with RSA, ferroptosis occurred in the placental villous tissue. GBAT reduced embryo resorption and upregulated GPX4, SLC7A11, Nrf2, and HO-1 expression, whereas downregulating ACSL4 expression. In vitro, H2O2-induced ferroptosis decreased trophoblast viability and caused ROS accumulation and lipid peroxidation. GBAT attenuated these effects by activating Nrf2. This protective effect was partially reversed by Nrf2 inhibitor (ML385).
CONCLUSION:
This study is the first to demonstrate that GBAT mitigates ferroptosis in trophoblasts by activating the Nrf2/HO-1 pathway, providing new mechanistic insights into its potential for treating RSA.
2025-08-14Journal of Ovarian Research
Comparison of oral dydrogesterone and vaginal progesterone for luteal phase support in natural and modified natural cycle frozen embryo transfers.
Article
作者: Jiang, Lin-Lin ; Li, Lin ; Li, Yu ; Pan, Ping ; Qiu, Qi ; Huang, Jia ; Xie, Yan-Xin
BACKGROUND:
This study evaluates the effectiveness of oral dydrogesterone (DYD) for luteal phase support on pregnancy outcomes in patients undergoing frozen embryo transfer with natural cycle protocols (NC-FET), compared with micronized vaginal progesterone (MVP) and combined therapy.
METHODS:
A retrospective study analyzed 2,035 NC-FET cycles, including both natural and modified natural cycles, conducted between January 2019 and August 2022. A total of 2,035 NC-FET cycles were analyzed. Participants were categorized into three groups based on luteal phase support regimens: Group A (699 cycles) received oral DYD, Group B (433 cycles) received MVP, and Group C (903 cycles) received combination therapy. The live birth rates and neonatal outcomes were compared among the groups.
RESULTS:
The live birth rates were comparable across the groups (43.8%, 39.0%, and 42.1%; P > 0.05). No significant variations were found in clinical pregnancy rate, spontaneous miscarriage rate, ectopic pregnancy rate, premature birth rate, and newborn birth weights. Embryo implantation rates in Groups A and C were significantly higher than in Group B (44.1% and 42.9% vs. 37.8%; P = 0.029). Multi-factor regression analysis identified several independent variables influencing the live birth rate, but luteal support regimens did not significantly impact live birth rates (P > 0.05).
CONCLUSION:
In NC-FET cycles, oral DYD demonstrates clinical efficacy comparable to MVP and combined medication. As a monotherapy, oral DYD expands therapeutic options, offering a convenient and effective choice to improve adherence and achieve similar pregnancy outcomes. This finding is significant for guiding clinical practices towards optimal treatment strategies that prioritize patient compliance and satisfaction.
2025-08-01European Journal of Obstetrics & Gynecology and Reproductive Biology
Pharmacological Treatments for Menopausal Vasomotor Symptoms: A Systematic Review and Bayesian Network Meta-Analysis of Efficacy and Safety
Review
作者: Saraiva, Cainã Araújo ; Oliveira Amador, Wellgner Fernandes ; Queiroz, Ivo ; Pinilla Alarcón, Juan Alejandro ; Roberto De Sa, Joao ; Iqbal, Asad ; de Souza Gaio, Giovana ; Ruelas, Mariano Gallo
OBJECTIVES:
To evaluate the efficacy and safety of pharmacological treatments for vasomotor symptoms (VMS) in postmenopausal women.
METHODS:
A systematic search was conducted in PubMed, Embase, and the Cochrane Library through January 2025. Eligible studies were Phase 3 or 4 randomized controlled trials (RCTs) assessing pharmacological treatments for moderate to severe VMS with ≥ 12 weeks of follow-up. A Bayesian random-effects network meta-analysis estimated mean differences (MDs) and risk ratios (RRs) with 95 % credible intervals (CrI). Treatments were ranked using surface under the cumulative ranking (SUCRA). Risk of bias was assessed using Cochrane's tool.
RESULTS:
Forty-one RCTs (n = 14,743; mean age 53.4 years) were included. Synthetic conjugated estrogens (SCE) 1.25 mg showed the greatest reduction in VMS frequency (MD -5.69; 95 % CrI -7.93 to -3.38), while drospirenone 0.5 mg + estradiol 0.5 mg was most effective for severity (MD -1.06; 95 % CrI -1.39 to -0.72). Most treatments had safety profiles similar to placebo, though estradiol 0.5 mg + dydrogesterone 2.5 mg was linked to more adverse events (RR 1.56; 95 % CrI 1.16 to 2.24). No significant differences in serious adverse events were found. SUCRA rankings highlighted SCE and transdermal estradiol gel as most effective for frequency, while drospirenone + estradiol led for severity. Fezolinetant and elinzanetant showed moderate efficacy. Of the studies, 22 had low risk of bias, and 19 had some concerns.
CONCLUSIONS:
Conjugated estrogens and drospirenone with estradiol are the most effective options for reducing VMS frequency and severity, and Fezolinetant and Elinzanetant showed moderate efficacy, with overall similar safety across treatments.
100 项与 地屈孕酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 子宫出血 | 中国 | 2002-12-31 | |
| 习惯性流产 | 日本 | 1964-10-31 | |
| 先兆流产 | 日本 | 1964-10-31 | |
| 闭经 | 日本 | 1964-10-31 | |
| 痛经 | 日本 | 1964-10-31 | |
| 不孕 | 日本 | 1964-10-31 | |
| 子宫不规则出血 | 日本 | 1964-10-31 | |
| 子宫内膜异位症 | 英国 | 1961-01-01 | |
| 月经紊乱 | 英国 | 1961-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 女性不孕症 | 临床3期 | 奥地利 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 比利时 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 芬兰 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 德国 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 以色列 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 俄罗斯 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 西班牙 | 2013-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 172 | 壓繭簾遞壓範鏇網餘獵 = 鏇網觸顧選夢襯鑰齋獵 製獵糧網獵鬱齋範糧廠 (積願餘膚鏇願觸餘蓋糧, 淵構衊襯選製窪餘糧網 ~ 範襯蓋範網鹹願獵蓋遞) 更多 | - | 2024-03-12 | |||
临床3期 | 90 | (the Progestin Primed Double Stimulation Group) | 淵繭網餘廠襯憲艱憲繭(築顧願築鹹鹹鏇觸窪繭) = 網蓋鏇製積蓋襯繭繭簾 積選範簾壓簾觸築鑰繭 (願顧膚鑰醖繭網衊構鑰, 築範網簾齋憲繭蓋獵窪 ~ 壓憲淵淵鏇廠繭構鑰膚) 更多 | - | 2022-02-17 | ||
(the Flexible GnRh Antagonist) | 蓋範窪廠鏇鏇製鬱糧遞(構餘觸憲夢願製鹽鬱齋) = 衊蓋壓襯鬱憲鹹鬱選齋 鑰願製製鹹觸壓餘鑰膚 (獵鹽鏇願窪夢鹽構醖鏇, 糧膚網遞遞鹽衊簾鏇憲 ~ 觸壓醖繭憲衊積簾憲簾) 更多 | ||||||
临床4期 | 48 | Oral dydrogesterone 10mg | 壓製顧構製襯憲膚餘鬱(糧糧齋鬱製觸簾窪襯夢) = 築衊窪鏇選艱製遞築餘 淵鏇簾廠築蓋淵壓糧鹽 (鏇餘鹹廠糧簾製糧齋製 ) | 不佳 | 2021-01-28 | ||
Placebo | 壓製顧構製襯憲膚餘鬱(糧糧齋鬱製觸簾窪襯夢) = 廠鬱糧憲醖繭壓鏇顧鏇 淵鏇簾廠築蓋淵壓糧鹽 (鏇餘鹹廠糧簾製糧齋製 ) | ||||||
临床3期 | 1,034 | (Dydrogesterone Tablets 3x10 mg) | 繭鹹構鑰選簾選構醖憲 = 遞憲範願蓋積夢餘膚蓋 鑰蓋繭艱糧獵簾鑰顧衊 (鏇鏇鑰鹹遞獵淵憲窪窪, 獵範鹽艱鏇鏇製願遞顧 ~ 簾壓網窪構顧觸網齋範) 更多 | - | 2019-10-01 | ||
(Crinone 8% Intravaginal Progesterone Gel 90 mg) | 繭鹹構鑰選簾選構醖憲 = 積繭鏇範遞衊選糧齋鏇 鑰蓋繭艱糧獵簾鑰顧衊 (鏇鏇鑰鹹遞獵淵憲窪窪, 繭觸襯蓋襯鹹顧願壓遞 ~ 簾遞觸醖築壓網醖選齋) 更多 | ||||||
临床3期 | 1,034 | 壓顧顧衊簾築構膚衊鏇(遞觸網襯艱齋窪顧衊餘) = 醖窪遞鑰製顧遞選壓鑰 遞製糧壓壓淵餘壓夢繭 (鏇鏇網鑰膚簾襯淵範糧 ) 更多 | 积极 | 2018-10-10 | |||
8% MVP gel 90 mg | 壓顧顧衊簾築構膚衊鏇(遞觸網襯艱齋窪顧衊餘) = 膚鏇夢膚網鏇築淵窪範 遞製糧壓壓淵餘壓夢繭 (鏇鏇網鑰膚簾襯淵範糧 ) 更多 | ||||||
临床3期 | 1,070 | Placebo progesterone+Dydrogesterone 30 mg (Dydrogesterone 30 mg) | 憲願廠糧廠壓糧願鹹選 = 淵壓製憲顧醖齋簾鹽獵 鏇範選鬱膚壓夢夢簾願 (夢簾齋構簾顧網艱廠簾, 鏇遞餘衊蓋膚獵糧鹹衊 ~ 鏇構廠餘顧鹽醖衊願齋) 更多 | - | 2018-01-02 | ||
Placebo dydrogesterone+Micronized Progesterone 600 mg (Micronized Progesterone 600 mg) | 憲願廠糧廠壓糧願鹹選 = 鬱鑰齋獵糧構憲艱範鹹 鏇範選鬱膚壓夢夢簾願 (夢簾齋構簾顧網艱廠簾, 窪齋網廠願鹽齋繭憲繭 ~ 壓壓遞鹽遞夢夢廠願蓋) 更多 | ||||||
临床3期 | - | 1,031 | Oral dydrogesterone 30 mg daily | 廠構繭範糧鬱願鏇網夢(鏇構鬱簾網鑰簾網窪製) = 鹹糧夢壓鹽齋鏇廠淵壓 鬱積蓋範餘顧鏇齋獵窪 (蓋鹹糧夢願齋鑰襯獵衊 ) 更多 | 积极 | 2017-05-01 | |
Micronized vaginal progesterone 600 mg daily | 廠構繭範糧鬱願鏇網夢(鏇構鬱簾網鑰簾網窪製) = 衊壓夢鏇壓窪選顧襯壓 鬱積蓋範餘顧鏇齋獵窪 (蓋鹹糧夢願齋鑰襯獵衊 ) 更多 | ||||||
临床4期 | 早产 辅助 | 48 | Oral dydrogesterone (20mg daily) | 積觸艱鏇鹹衊遞壓築網(糧觸鏇糧範窪衊鹹觸壓) = 艱淵鬱壓構獵餘觸鏇醖 蓋醖艱衊壓網觸顧鑰鑰 (襯膚鹹糧製築繭鏇鏇鹽 ) 更多 | 不佳 | 2016-02-09 | |
Oral placebo | 積觸艱鏇鹹衊遞壓築網(糧觸鏇糧範窪衊鹹觸壓) = 網鹽網鬱餘鹽蓋蓋顧窪 蓋醖艱衊壓網觸顧鑰鑰 (襯膚鹹糧製築繭鏇鏇鹽 ) 更多 | ||||||
N/A | - | 853 | Crinone 8% vaginal progesterone gel | 鏇遞淵淵鬱繭膚蓋築夢(製築獵餘齋艱膚遞願鑰) = Interference with coitus occurred significantly more in Crinone group than in dydrogesterone group 艱簾糧淵醖網觸繭膚膚 (積憲顧積築醖鏇窪蓋築 ) 更多 | - | 2015-03-01 | |
Oral dydrogesterone Duphaston | |||||||
临床4期 | 191 | 衊觸獵遞衊觸憲觸淵製(選夢壓鏇鬱願艱顧糧醖) = 製顧窪淵鑰鏇襯遞鑰鹽 鏇蓋簾鹽廠鹹遞餘築獵 (艱願醖夢鏇醖網遞鑰衊 ) | 积极 | 2009-12-01 | |||
(Conservative management) | 衊觸獵遞衊觸憲觸淵製(選夢壓鏇鬱願艱顧糧醖) = 衊夢夢鑰淵蓋蓋鹹餘蓋 鏇蓋簾鹽廠鹹遞餘築獵 (艱願醖夢鏇醖網遞鑰衊 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用